ORION-8: Long-term Extension of Inclisiran in High CV Risk and Elevated LDL-C

Phase 3, open-label, single-arm trial of inclisiran in atherosclerotic cardiovascular disease (ASCVD), heterozygous familial hypercholesterolemia (HeFH), hypercholesterolemia and 1 more, sponsored by Novartis. Primary endpoints: Proportion of Subjects Achieving Global Lipid Targets for Their Level of ASCVD Risk at Day 1080 and Incidence of Treatment-emergent Adverse Events at Day 1080. Started Apr 2019; status: completed.